Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Variable Rate Preferred Invesco ETF (VRP)

Variable Rate Preferred Invesco ETF (VRP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Invesco
  • Assets Under Management 1,551,840,000
  • Market Capitalization, $K 1,551,840
  • Shares Outstanding, K 61,000
  • 60-Month Beta 0.23
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 1.34 (5.27%)
  • Most Recent Dividend 0.112 on 09/23/19
  • Management Fee 0.50%
  • Sectors:

    ETFs - Mixed Asset

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.25 +0.75%
on 09/16/19
25.49 -0.20%
on 09/20/19
+0.10 (+0.39%)
since 09/13/19
3-Month
25.06 +1.52%
on 08/20/19
25.50 -0.24%
on 09/09/19
+0.34 (+1.35%)
since 07/12/19
52-Week
22.26 +14.29%
on 12/27/18
25.50 -0.24%
on 09/09/19
+0.84 (+3.41%)
since 10/12/18

Most Recent Stories

More News
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive interim data from a Phase 2 trial with...

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO, will present at the H.C. Wainwright...

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019

Initiated Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler ("DPI") formulation...

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that it will report its audited financial results...

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that the Company's management team will conduct...

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces two senior appointments to its clinical team. They will lead the Phase...

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2b dose-ranging study evaluating...

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019

Nebulized ensifentrine as add-on to dual bronchodilator therapy for COPD demonstrated additional increase in lung function on top of maximum current therapy in three-day Phase 2 clinical trial

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)
Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present data from its chronic obstructive...

VRP : 25.44 (+0.04%)
VRNA : 4.06 (-4.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade VRP with:

Fund Summary

The Invesco Variable Rate Preferred ETF is based on the Wells Fargo Hybrid and Preferred Securities Floating and Variable Rate Index. The Fund will generally invest at least 90% of its total assets in preferred securities that comprise the Index. The Index is a market capitalization-weighted index designed...

See More

Top 10 Holdings

Name % Holdings
General Electric Co 2.86%
JPMorgan Chase & Co 2.36%
GMAC Capital Trust I 1.54%
Bank of America Corp 1.39%
Wachovia Capital Trust III 1.37%
Citigroup Capital XIII 1.36%
JPMorgan Chase & Co 1.35%
JPMorgan Chase & Co 1.24%
Vodafone Group PLC 1.21%
JPMorgan Chase & Co 1.21%

See More

Key Turning Points

2nd Resistance Point 25.50
1st Resistance Point 25.47
Last Price 25.44
1st Support Level 25.41
2nd Support Level 25.38

See More

52-Week High 25.50
Last Price 25.44
Fibonacci 61.8% 24.26
Fibonacci 50% 23.88
Fibonacci 38.2% 23.50
52-Week Low 22.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar